|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C24H29N5O3.C24H29NO5.5/2H2O.3Na |
|||
| Molecular Weight | 915.98 | CAS No. | 936623-90-4 | |
| Solubility (25°C)* | In vitro | Water | 100 mg/mL (109.17 mM) | |
| DMSO | 30 mg/mL (32.75 mM) | |||
| Ethanol | 9 mg/mL (9.82 mM) | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Sacubitril/valsartan (LCZ696, Sacubitril, Valsartan), consisting of valsartan and sacubitril in 1:1 molar ratio, is an orally bioavailable, dual-acting angiotensin receptor-neprilysin inhibitor (ARNi) for hypertension and heart failure. Phase 3. | |
|---|---|---|
| Targets |
|
|
| In vivo | In double-transgenic rats overexpressing human renin and angiotensinogen and plasma atrial natriuretic peptide immunoreactivity, LCZ696 (60 mg/kg p.o.) induces a dose-dependent and long-lasting reduction in mean arterial pressure (MAP), and stimulates a rapid and dose-dependent augmentation of plasma ANP immunoreactivity. [1] In rat myocardial infarction (MI) model, LCZ696 (68 mg/kg p.o.) attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy. [2] |
Protocol (from reference)
| Animal Study: |
|
|---|
References
|
Customer Product Validation
-
Data from [Data independently produced by , , J Mol Cell Cardiol, 2017, 108:138-148]
-
Data from [Data independently produced by , , RSC Adv, 2017, doi:10.1039/C7RA01404J]
Selleck's Sacubitril/valsartan (LCZ696) has been cited by 11 publications
| LCZ696 (sacubitril/valsartan) inhibits pulmonary hypertension induced right ventricular remodeling by targeting pyruvate dehydrogenase kinase 4 [ Biomed Pharmacother, 2023, 162:114569] | PubMed: 37001183 |
| Sacubitril/valsartan alleviates sepsis-induced acute lung injury via inhibiting GSDMD-dependent macrophage pyroptosis in mice [ FEBS J, 2023, 290(8):2180-2198] | PubMed: 36471663 |
| Sacubitril Valsartan Enhances Cardiac Function and Alleviates Myocardial Infarction in Rats through a SUV39H1/SPP1 Axis [ Oxid Med Cell Longev, 2022, 2022:5009289] | PubMed: 36193085 |
| Sacubitril Valsartan Enhances Cardiac Function and Alleviates Myocardial Infarction in Rats through a SUV39H1/SPP1 Axis [ Oxid Med Cell Longev, 2022, 2022:5009289] | PubMed: 36193085 |
| Sacubitril/valsartan reduces endoplasmic reticulum stress in a rat model of doxorubicin-induced cardiotoxicity [ Arch Toxicol, 2022, 96(4):1065-1074] | PubMed: 35152301 |
| Direct actions of dapagliflozin and interactions with LCZ696 and spironolactone on cardiac fibroblasts of patients with heart failure and reduced ejection fraction [ ESC Heart Fail, 2022, 10.1002/ehf2.14186] | PubMed: 36303443 |
| Additive protective effects of sacubitril/valsartan and bosentan on vascular remodelling in experimental pulmonary hypertension [ Cardiovasc Res, 2021, 117(5):1391-1401] | PubMed: 32653925 |
| LCZ696 Possesses a Protective Effect Against Homocysteine (Hcy)-Induced Impairment of Blood-Brain Barrier (BBB) Integrity by Increasing Occludin, Mediated by the Inhibition of Egr-1 [ Neurotox Res, 2021, 10.1007/s12640-021-00414-1] | PubMed: 34542838 |
| LCZ696 improves cardiac function via alleviating Drp1-mediated mitochondrial dysfunction in mice with doxorubicin-induced dilated cardiomyopathy. [Xia Y, et al. J Mol Cell Cardiol, 2017, 108:138-148] | PubMed: 28623750 |
| A metabolomics approach to profiling the cardioprotective effect of LCZ696, an angiotensin receptor-neprilysin inhibitor, on ischemia induced heart failure† [Yan Xia, et al. RSC Adv, 2017, 10.1039/C7RA01404J] |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.